• PharmaEssentia will present BESREMi research at the American Society of Hematology annual meeting, December 12-15, 2026, in New Orleans.
• The program includes one oral presentation, nine posters and five online publications, covering clinical, molecular and real-world evidence.
• Polycythemia vera studies examine sustained remission following treatment discontinuation and molecular improvements during long-term therapy despite stable blood responses.
• The research follows recent FDA clearance for adults with essential thrombocythemia, BESREMi's second US indication alongside polycythemia vera.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PharmaEssentia Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202611060900BIZWIRE_USPR_____20261106_BW675751) on November 06, 2026, and is solely responsible for the information contained therein.